UBS Group
LEGN icon

UBS Group’s Legend Biotech LEGN Stock Holding History

UBS Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,200
Closed -$895K – 9818
2024
Q2 		$895K Sell
20,200
-13,700
-40% -$632K ﹤0.01% 4517
2024
Q1 		$1.9M Buy
33,900
+21,400
+171% +$1.29M ﹤0.01% 4004
2023
Q4 		$752K Sell
12,500
-42,500
-77% -$2.69M ﹤0.01% 4743
2023
Q3 		$3.69M Buy
+55,000
New +$3.82M ﹤0.01% 2868

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group's LEGN Position: Q1 2026 in Review

UBS Group increased its Legend Biotech (LEGN) stake by 36% in Q1 2026, buying an estimated $1.54M and bringing the position to 305,214 shares worth $5.52M. The position accounts for ﹤0.01% of the portfolio, ranked #3983.

UBS Group first reported a position in LEGN in Q2 2020 and has held it in 24 quarters since. The position peaked at $36.3M in Q2 2025. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • UBS Group held 305,214 shares of Legend Biotech worth $5.52M as of Q1 2026.
  • UBS Group bought 80,602 Legend Biotech shares in Q1 2026, an estimated $1.54M.
  • Legend Biotech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3983 holding.
  • UBS Group first reported a position in Legend Biotech in Q2 2020 and has held it in 24 quarters since.
  • UBS Group's Legend Biotech position peaked at $36.3M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.